Momenta, Sandoz Play Patent Defense For A Change, Seek Injunction To Prevent Teva From Launching Generic Lovenox
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms claim Teva, which now seems close to approval, cannot manufacture enoxaparin to match Sanofi's branded Lovenox without infringing Momenta's manufacturing process.
You may also be interested in...
New Delay For Teva's Generic Lovenox Bodes Well For Sandoz/Momenta Sales
A "minor deficiency letter" from FDA's Office of Generic Drugs seeks responses to questions about Teva's enoxaparin ANDA, the company says.
New Delay For Teva's Generic Lovenox Bodes Well For Sandoz/Momenta Sales
A "minor deficiency letter" from FDA's Office of Generic Drugs seeks responses to questions about Teva's enoxaparin ANDA, the company says.
Court Backs FDA Rationale For Approving Generic Lovenox
A Washington, D.C. district court judge says FDA had the right to request additional immunogenicity tests of Sandoz's generic in denying Sanofi-Aventis's request to overturn approval of the drug.